Key facts
- This page summarizes Michael Craig Pine's Form 4 filing for EyePoint Pharmaceuticals, Inc. (EYPT).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 30 May 2023, 17:14.
Michael Craig Pine - 25 May 2023 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)
- Reporting relationship
- Chief Corp Dev.&Strat. Officer
- Issuer ticker
- EYPT
- Reported as of
- 25 May 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 30 May 2023, 17:14:02 UTC
- Prior SEC filing
- 10 Jan 2023
- Next SEC filing
- 22 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ron Honig, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Craig Pine filed Form 4 for EyePoint Pharmaceuticals, Inc. (EYPT) on 30 May 2023.
Change
- Previous filing in this sequence was filed on 10 Jan 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EYPT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +15,000
- Change %
- Price
- $0.000000
- Shares after
- 15,000
- Date
- 25 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $5.93
- Footnotes
- F1
EYPT
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +7,500
- Change %
- Price
- $0.000000
- Shares after
- 7,500
- Date
- 25 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,500
- Exercise price
- $0.000000
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The option to purchase will vest and become exercisable as follows: 25% at May 25th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.
Footnote F2
The restricted stock units will vest in three ratable annual installments beginning May 25, 2024.